Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Late-stage Biopharmaceutical Company Granted FDA Approval For Orphan Drug Designation

Breakthrough in Combat Against Sudan Ebolavirus: FDA Grants Orphan Drug Designation to Soligenix's SuVax™.
The U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation to Soligenix, Inc. (NASDAQ: SNGX) for their pioneering treatment, SuVax™. This treatment is aimed at the prevention and post-exposure prophylaxis of Sudan Ebolavirus infection, a critical unmet medical need that poses a global health threat. Soligenix, a late-stage biopharmaceutical company, is at the forefront of developing and commercializing products to treat rare diseases where the current medical response is insufficient. Their innovative SuVax™ vaccine stands out as a beacon of hope against Sudan Virus Disease, caused by the Sudan Ebolavirus, for which no treatment or vaccine is currently available. $Soligenix(SNGX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
Translate
Report
4381 Views
Comment
Sign in to post a comment
    117Followers
    0Following
    257Visitors
    Follow